Component

11-nor-9-carboxy-delta-9-tetrahydrocannabinol

11-nor-9-carboxy-delta-9-tetrahydrocannabinol. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference.

    The CYP2C9*3 variant allele → Plasma THC concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/thc-research/19005461.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e", "start_char": 0, "end_char": 601, "text_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e"}
    experimental_model
    Oral THC in 43 healthy volunteers genotyped for CYP2C9
    exposure
    Oral THC across CYP2C9 genotypes
    limitations
    A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend.
    nutrient_topic
    THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
    organism
    Human
    plain_language
    People with two copies of one variant get three times the drug exposure from the same dose.
    primary_references
    [thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213
    tissue_or_cell_type
    Whole body
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 530–541

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Oral THC in 43 healthy volunteers genotyped for CYP2C9 · source_derived_draft · unverified_draft

    ### thc-cyp2c9-exposure The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference. Condition category: machinery_impairment nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: People with two copies of one variant get three times the drug exposure from the same dose. organism: Human tissue_or_cell_type: Whole body experimental_model: Oral THC in 43 healthy volunteers genotyped for CYP2C9 limitations: A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend. exposure: Oral THC across CYP2C9 genotypes evidence_span: {"source_cache": "artifacts/thc-research/19005461.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e", "start_char": 0, "end_char": 601, "text_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e"} [thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213
    Complete structured claim and evidence

  2. Plasma cannabinoid pharmacokinetics following controlled oral THC and oromucosal cannabis extract administration resolved the time courses of THC and its metabolites.

    Delta-9-tetrahydrocannabinol / THC → 11-hydroxy-delta-9-tetrahydrocannabinol source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/thc-research/21078841.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9", "start_char": 0, "end_char": 1727, "text_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9"}
    experimental_model
    Controlled oral THC and oromucosal cannabis extract with serial plasma sampling
    exposure
    Controlled oral THC and oromucosal extract dosing
    limitations
    A controlled human pharmacokinetic study with the metabolites measured. Oral and oromucosal routes only; it does not describe smoked exposure.
    nutrient_topic
    THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
    organism
    Human
    plain_language
    The drug is measured alongside the two metabolites it becomes.
    primary_references
    [thc-p21078841] Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. (2011). https://pubmed.ncbi.nlm.nih.gov/21078841/ DOI: 10.1373/clinchem.2010.152439
    tissue_or_cell_type
    Plasma

    THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 517–528

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Controlled oral THC and oromucosal cannabis extract with serial plasma sampling · source_derived_draft · unverified_draft

    ### thc-thc-metabolites Plasma cannabinoid pharmacokinetics following controlled oral THC and oromucosal cannabis extract administration resolved the time courses of THC and its metabolites. Condition category: normal nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: The drug is measured alongside the two metabolites it becomes. organism: Human tissue_or_cell_type: Plasma experimental_model: Controlled oral THC and oromucosal cannabis extract with serial plasma sampling limitations: A controlled human pharmacokinetic study with the metabolites measured. Oral and oromucosal routes only; it does not describe smoked exposure. exposure: Controlled oral THC and oromucosal extract dosing evidence_span: {"source_cache": "artifacts/thc-research/21078841.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9", "start_char": 0, "end_char": 1727, "text_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9"} [thc-p21078841] Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. (2011). https://pubmed.ncbi.nlm.nih.gov/21078841/ DOI: 10.1373/clinchem.2010.152439
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards